The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy

Cancer

Volumn 118, Issue 2, 2012, Pages 365-370

  Macfarlane, Robyn ^a   Heng, Daniel Y C ^b   Xie, Wanling ^c   Knox, Jennifer J ^d   McDermott, David F ^e   Rini, Brian I ^f   Kollmannsberger, Christian ^a   Choueiri, Toni K ^c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Bevacizumab; Glomerular filtration rate; Metastatic renal cell carcinoma; Renal function; Sorafenib; Sunitinib

Indexed keywords

BEVACIZUMAB; SORAFENIB; SUNITINIB; VASCULOTROPIN;

ADULT; AGE; ANEMIA; ARTICLE; BRAIN METASTASIS; CALCULATION; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; DRUG TARGETING; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCALCEMIA; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MODIFICATION OF DIET IN RENAL DISEASES FORMULA; MULTICENTER STUDY (TOPIC); NEPHRECTOMY; NEUTROPHILIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; THROMBOCYTOSIS; TIME TO TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84855501328     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26201     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Gupta S, Parso V, Heilbrun L, et al. Safety and efficacy analysis of sunitinib, bevacizumab, and m-tor inhibitors in metastatic renal cell cancer patients with renal insufficiency [abstract]. J Clin Oncol. 2009;27(15s). Abstract 5198.
3. Izzedine H, Etienne-Grimaldi MC, Renee N, et al. Pharmacokinetics of sunitinib in haemodialysis. Ann Oncol. 2009;20:190-192.
4. Vickers MM, Heng DY, Hemmelgarn B, Eigl BJ. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2009;7:E104-E106.
5. Khosravan R, Toh M, Garrett M, et al. Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol. 2010;50:472-481.
6. Khan G, Golshayan A, Elson P, et al. Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. Ann Oncol. 2010;21:1618-1622.
7. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794-5799.
8. Motzer RJ, Bacik J, Murphy BA, et al. Interferon alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289-296. (Pubitemid 34032623)
9. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007;110:543-550. (Pubitemid 47106142)
10. Motzer RJ, Bukowski RM, Figlin RA, et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2008;113:1552-1558.
11. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470. (Pubitemid 29135798)
12. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:s1-s266.
13. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;343:1655-1659. (Pubitemid 33126820)
14. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966-970. (Pubitemid 32913522)
15. Zini L, Capitanio U, Perrotte P, et al. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology. 2008;73:342-346.
16. Zini L, Perrotte P, Jeldres C, et al. Nephrectomy improves the survival of patients with locally advanced renal cell carcinoma. BJU Int. 2008;102:1610-1614.
17. Jeldres C, Baillargeon-Gagne S, Liberman D, et al. A population- based analysis of the rate of cytoreductive nephrectomy for metastatic renal cell carcinoma in the united states. Urology. 2009;74:837-841.
18. Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol. 2009;27:1800-1805.
19. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473-2483. (Pubitemid 43855050)
20. Zastrow S, Froehner M, Platzek I, et al. Treatment of metastatic renal cell cancer with sunitinib during chronic hemodialysis. Urology. 2009;73:868-870.